MHC class II-HPV16 E7 peptide-T-cell receptor complex (MHC II-HPV16 E7-TCR complex)

The MHC class II-HPV16 E7 peptide-T-cell receptor (TCR) complex is a tripartite molecular assembly essential for the immune recognition of cells infected with human papillomavirus type 16 (HPV16) [1, 10]. This complex consists of an MHC class II molecule (such as HLA-DRB1*04:01) presenting a processed peptide epitope from the HPV16 E7 oncoprotein to a specific TCR on the surface of CD4+ T cells [10, 13]. The E7 oncoprotein is a primary driver of oncogenesis in HPV-related malignancies, including cervical, oropharyngeal, and anal cancers, and its continuous expression in tumor cells makes it a highly specific target for immunotherapy [8, 16]. Therapeutic strategies targeting this complex include the use of synthetic long peptide vaccines, such as ISA101, which induce the endogenous formation of these complexes to prime and expand E7-specific T cells [2, 3, 9]. Additionally, adoptive cell therapies utilizing T cells engineered with high-avidity TCRs (TCR-T) are being investigated to provide a robust anti-tumor response by directly targeting E7-presenting cells [1, 6, 11]. Activation of the CD4+ T cells through this complex results in the secretion of pro-inflammatory cytokines like interferon-gamma and can orchestrate a broader immune response, including the recruitment of CD8+ cytotoxic T cells, to eradicate tumor cells and overcome the immunosuppressive tumor microenvironment [10, 19].

Other names

HPV16 E7-specific MHC II-restricted TCR complexHLA-DRB1*04:01-E7 peptide-TCR complexCD4+ T-cell receptor-HPV16 E7-MHC II complexMHC II-HPV16 E7-CD4 TCR complex

T-cell receptor-mediated recognition and activation of CD4+ T cells leading to anti-tumor immune responses and direct or indirect tumor cell killing [10, 19].